Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer.

Future Oncol · 2025 · PMC12051594 · PMID 40129250

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Over the first 26 weeks, EV/P resulted in significantly improved functioning across domains including physical, cognitive and role functioning, with borderline significant improvement in emotional and social functioning.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.